WINNIPEG, Manitoba, April 18, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0)
(the "Company" or "3DS"), is pleased to announce that the Company will relocate its corporate offices to the MaRS Discovery
District (“MaRS”) in Toronto this spring. Following a rigorous screening process, 3DS was selected by MaRS Venture Services to join
a growing list of promising Canadian healthcare companies that are moving to one of the world’s largest innovation hubs.
"3D Signatures is thrilled to become a member of the MaRS community, working alongside other like-minded
companies in a state-of-the-art complex designed to cultivate innovation and entrepreneurship,” commented 3DS’ CEO, Jason
Flowerday. “This move offers us immediate access to a broad range of corporate and clinical resources, affordable and flexible
laboratory space, and a network of potential collaborators and mentors to help us grow our business, all in one of the most
desirable locations in Canada.”
MaRS supports promising companies tackling key challenges in the health, cleantech, finance and commerce
industries, as well as work and learning sectors, as they start, grow and scale.
As part of the MaRS community, 3DS will not only have access to a state-of-the-art facility, co-working and
laboratory space, but also key opinion leaders, potential collaborators and funding partners, and a wide range of business and
venture services to support the Company’s growth.
“The move to MaRS offers 3D Signatures a number of benefits that go beyond conventional lab and office space,
and we expect this relocation to pay off immediately as we work towards validation and commercialization of our diagnostic
pipeline, starting with our Hodgkin’s lymphoma and prostate cancer tests,” added Flowerday.
The Company is expected to complete the relocation to MaRS by April 30, 2017.
About 3DS
3DS (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform
based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical
studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform
technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is
designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the
Company’s new website at http://www.3dsignatures.com.
Forward-Looking Information
This news release includes forward-looking statements that are subject to risks and uncertainties.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of
the Company to be materially different from the historical results or from any future results expressed or implied by such
forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking.
Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance and actual results or developments may differ materially from those in
forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results
expressed or implied by forward-looking information include, among other things: market demand; technological changes that
could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition;
existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and
regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the
Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of
infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in
laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such
statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not
assume any obligation to update any forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Hugh Rogers VP Corporate Finance 604-428-8842 investors@3dsignatures.com OR Stephen Kilmer Investor Relations 647-872-4849 stephen.kilmer@3dsignatures.com
